Procurement of drugs for schistosomiasis and intestinal helminths control programmes in African countries
The estimated need for 2004 is approximately 11 million praziquantel tablets and 4 million albendazole/mebendazole tablets Over the next 5 years it is likely that the market for SCI supported countries will reach 75 million praziquantel and 25 million albendazole tablets. For the 2004 requirements, praziquantel and albendazole will be procured centrally by Imperial College for the countries Burkina Faso, Cameroon, Mali, Niger, Tanzania and Zambia. The following companies are considered possibles to bid for the praziquantel and/or albendazole requirements during 2004.
Any other companies not on this list which are interested in supplying SCI with praziquantel (600 mg tablets) or albendazole (400 mg tablets) are invited to examine the procurement website at Imperial College and submit their company profile. For 2005 and beyond, all drug procurement will be carried out by the countries themselves. In order to be able to respond to a tender, each company will need to register their praziquantel and albendazole products individually in each country. On request SCI staff are available to assist any company in the registration process. For details of how SCI can assist in the registration process please email to schisto1@imperial.ac.uk and copy to sciuser@imperial.ac.uk |
For
the control programmes in the SCI countries supplies of praziquantel (600 mg
tablets) for control of schistosomiasis and albendazole (400mg) and/or
mebendazole (500mg) against intestinal helminths will be procured.